vs
CorMedix Inc.（CRMD）与RMR GROUP INC.（RMR）财务数据对比。点击上方公司名可切换其他公司
CorMedix Inc.的季度营收约是RMR GROUP INC.的1.9倍（$128.6M vs $66.7M）
CorMedix Inc.是一家处于商业阶段的生物制药企业，专注于开发及商业化用于预防和治疗感染性、炎症性及心肾疾病的创新治疗产品，核心管线针对导管相关血流感染，主要服务北美、欧洲的重症监护及长期透析患者群体。
RMR集团是总部位于美国的另类资产管理企业，核心业务聚焦不动产及相关投资，覆盖商业地产、住宅物业、基础设施等赛道，服务全球核心市场的机构投资者、高净值人士及零售客户。
CRMD vs RMR — 直观对比
营收规模更大
CRMD
是对方的1.9倍
$66.7M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $128.6M | $66.7M |
| 净利润 | — | $12.2M |
| 毛利率 | 83.4% | — |
| 营业利润率 | 46.0% | 48.1% |
| 净利率 | — | 18.3% |
| 营收同比 | — | 40.8% |
| 净利润同比 | — | 91.1% |
| 每股收益（稀释后） | $0.20 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRMDRMR
| Q4 25 | $128.6M | $66.7M | ||
| Q3 25 | $104.3M | — | ||
| Q2 25 | $39.7M | — | ||
| Q1 25 | $39.1M | — |
净利润CRMDRMR
| Q4 25 | — | $12.2M | ||
| Q3 25 | $108.6M | — | ||
| Q2 25 | $19.8M | — | ||
| Q1 25 | $20.6M | — |
毛利率CRMDRMR
| Q4 25 | 83.4% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 95.3% | — | ||
| Q1 25 | 95.9% | — |
营业利润率CRMDRMR
| Q4 25 | 46.0% | 48.1% | ||
| Q3 25 | 49.2% | — | ||
| Q2 25 | 49.2% | — | ||
| Q1 25 | 51.5% | — |
净利率CRMDRMR
| Q4 25 | — | 18.3% | ||
| Q3 25 | 104.1% | — | ||
| Q2 25 | 49.9% | — | ||
| Q1 25 | 52.8% | — |
每股收益（稀释后）CRMDRMR
| Q4 25 | $0.20 | $0.71 | ||
| Q3 25 | $1.26 | — | ||
| Q2 25 | $0.28 | — | ||
| Q1 25 | $0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.5M | $49.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $405.3M | $232.7M |
| 总资产 | $826.1M | $687.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRMDRMR
| Q4 25 | $148.5M | $49.3M | ||
| Q3 25 | $55.7M | — | ||
| Q2 25 | $190.7M | — | ||
| Q1 25 | $77.5M | — |
股东权益CRMDRMR
| Q4 25 | $405.3M | $232.7M | ||
| Q3 25 | $374.1M | — | ||
| Q2 25 | $220.6M | — | ||
| Q1 25 | $114.9M | — |
总资产CRMDRMR
| Q4 25 | $826.1M | $687.1M | ||
| Q3 25 | $750.9M | — | ||
| Q2 25 | $252.6M | — | ||
| Q1 25 | $149.6M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.5M | $10.7M |
| 自由现金流经营现金流 - 资本支出 | $92.7M | — |
| 自由现金流率自由现金流/营收 | 72.1% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | — | 0.88× |
| 过去12个月自由现金流最近4个季度 | $172.8M | — |
8季度趋势，按日历期对齐
经营现金流CRMDRMR
| Q4 25 | $94.5M | $10.7M | ||
| Q3 25 | $30.9M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $19.7M | — |
自由现金流CRMDRMR
| Q4 25 | $92.7M | — | ||
| Q3 25 | $30.4M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $19.7M | — |
自由现金流率CRMDRMR
| Q4 25 | 72.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 75.4% | — | ||
| Q1 25 | 50.5% | — |
资本支出强度CRMDRMR
| Q4 25 | 1.3% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — |
现金转化率CRMDRMR
| Q4 25 | — | 0.88× | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RMR
| Management Service Incentive | $23.6M | 35% |
| Industrial Logistics Properties Trust | $15.1M | 23% |
| Managed Private Real Estate Capital | $11.1M | 17% |
| Office Properties Income Trust | $5.6M | 8% |
| Other Private Entities | $5.3M | 8% |
| RMR Residential | $3.4M | 5% |
| Sonesta International Hotels Corporation | $2.1M | 3% |
| Investment Advisory Management And Administrative Service | $1.2M | 2% |
